GRCL Gracell Biotechnologies Inc. Quarterly EPS earnings growth

Gracell Biotechnologies (GRCL) is recognized as a leader in CAR-T cell engineering via its FasTCAR platform for the treatment of hematological malignancies. The quarterly EPS growth rate reflects current dynamics, where 69.40 characterizes this valuation parameter. While the company is scaling tests through contract manufacturers, high costs and therapy safety risks may delay the business from reaching break-even.

Gracell Biotechnologies Inc. (GRCL) Year-over-year earnings per share growth for the last twelve months: for the period 07/04/2022 - 03/03/2024

Gracell (GRCL) - metric breakdowns and financial figures

- share price and expert price forecast:

Stock Price Gracell Biotechnologies Inc.|GRCL - Consensus Target

- market capitalization data:

Market Capitalization Gracell Biotechnologies Ltd|GRCL - Total Enterprise Value

- balance sheet net asset value indicators:

Net Assets per Single Share Gracell Biotechnologies|GRCL - Company Book Value|Market Value to Book Value Ratio gracellbio.com|GRCL - Aggregate Company Assets

- company liabilities and liquidity data:

- earnings and market multiples details:

GRCL - Company Net Income|Future Profit Gracell Biotechnologies|GRCL - Company Value to Net Income|Projected Price to Earnings Gracell Biotechnologies Ltd|GRCL - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Gracell Biotechnologies Ltd|GRCL - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Gracell Biotechnologies|GRCL - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months gracellbio.com|GRCL - Earnings per share increase in current year|Earnings growth forecast for next year Gracell Biotechnologies

- sales volume and revenue information:

GRCL - Revenue and Sales Volume|Company Projected Revenue Gracell Biotechnologies Inc.|GRCL - Price-to-Sales Ratio|Forward Price-to-Revenue Multiple Gracell Biotechnologies Ltd

Fundamental company analysis:Gracell Biotechnologies Inc. - GRCL

The recognition of Gracell Biotechnologies (GRCL) as a cell therapy leader following its acquisition by a pharma behemoth shifts the valuation of its assets into a realm of high market confidence. The quarterly earnings per share history, featuring the value 69.40, daily bridges the information gap between reports by measuring net income dynamics to identify overpayment risks during rallies or recovery potential during downturns.

Analysis of competing companies

LEGN: Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Sana Biotechnology Inc|AUTL (Autolus Pharma) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Allogene Corp ALLO|Year-over-year earnings per share growth for the last twelve months Cartesian Therapeutics (RNAC)|Year-over-year earnings per share growth for the last twelve months CLLS (cellectis.com)|Year-over-year earnings per share growth for the last twelve months Caribou Biosciences, Inc. CRBU|Instil Bio Inc. - Year-over-year earnings per share growth for the last twelve months|GNTA: Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months IPSC (Century Therapeutics)|JSPR: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Senti Biosciences SNTI|ADAP (Adaptimmune Therapeutics plc) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months CERo Therapeutics Holdings Inc. CERO|Year-over-year earnings per share growth for the last twelve months Alaunos Therapeutics (TCRT)|achillestx.com - Year-over-year earnings per share growth for the last 12 months|Quarterly EPS earnings growth CRGX (CARGO Therapeutics)|poseida.com (PSTX) - Earnings per share growth in annualized terms for the last twelve months|TSVT: Year-over-year net earnings per share growth for the last 12 months